Regenerative Medical Tech Group Faces Going Concern Doubt, Debt Defaults
Regenerative Medical Technology Group Inc. (RMTG) faces substantial doubt about its ability to continue as a going concern, as highlighted by its independent registered public accounting firm due to a net loss and capital deficiency. The company also has $1,157,935 in matured unsecured promissory notes currently in default, with a risk of accelerating up to $16.6 million in secured debt if formal demand is made. Despite these financial challenges, RMTG outlined a strategic outlook for 2026, focusing on optimizing its vertically integrated regenerative medicine ecosystem, expanding its clinical network, and integrating AI-driven personalization. The strategy includes leveraging its ISSCA educational platform, Cellgenic manufacturing, and global market expansion across Latin America, the Middle East, and Southeast Asia.
Key Highlights
- Independent auditor expressed substantial doubt about RMTG's ability to continue as a going concern.
- RMTG has $1,157,935 in unsecured promissory notes currently in default.
- Defaulted notes could trigger acceleration of up to $16.6 million in secured debt.
- Company is in debt restructuring talks and seeking additional financing.
- RMTG forecasts meaningful revenue acceleration and margin expansion in 2026.
- ISSCA executed 15 international events across five continents in 2025.
- 2025 ISSCA Global Summit in Cancún was attended by over 470 medical professionals.
- Company expanded operations into Latin America, Middle East, Southeast Asia, and Europe.